News Chasing BMS, Takeda trumpets TYK2 data in psoriasis Pharma group is hoping for big things, after splashing out $4bn upfront for the drug last year.
News AbbVie’s Skyrizi hits the spot in refractory psoriasis Antibody works when IL-17 inhibitors Like Novartis' Cosentyx and Lilly's Taltz fail.
News Dupixent works in hard-to-treat form of atopic dermatitis IL-4 inhibitor shows its worth in atopic hand-foot dermatitis unresponsive to corticosteroids.
News Merck suffers a setback in its TIGIT programme Missed endpoint in mid-stage study in lung cancer is a worry after other TIGIT failures.
News Concentra gatecrashes Jounce and Redx’ merger party Biotech interloper is led by Kevin Tang of Tang Capital management, which owns 10% of Jounce.
News UK Chancellor’s budget welcomed by biopharma sector Industry groups are happy with news on R&D tax credits, funding for MHRA, and investment zones.
News Teva makes its first M&A play in years, buying Emalex Teva has made its first pipeline-building acquisition in almost a decade, buying Tourette syndrome drug developer Emalex for up to $900m.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
